Results 171 to 180 of about 10,402 (207)
Some of the next articles are maybe not open access.
Pharmacokinetics of Pegylated Liposomal Doxorubicin
Clinical Pharmacokinetics, 2003Pegylated liposomal doxorubicin (doxorubicin HCl liposome injection; Doxil or Caelyx) is a liposomal formulation of doxorubicin, reducing uptake by the reticulo-endothelial system due to the attachment of polyethylene glycol polymers to a lipid anchor and stably retaining drug as a result of liposomal entrapment via an ammonium sulfate chemical ...
Alberto, Gabizon +2 more
openaire +2 more sources
Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin
Clinical Lymphoma and Myeloma, 2008Pegylated liposomal doxorubicin (PLD) is a liposomal formulation with a distinct pharmacokinetic profile characterized by an extended circulation time and a reduced volume of distribution. Biodistribution animal studies indicate preferential accumulation of PLD into various implanted mouse-human tumors, with an enhancement of liposomal drug tumor ...
Rebecca, Soloman, Alberto A, Gabizon
openaire +2 more sources
Biochimica Et Biophysica Acta - Biomembranes, 2004 The pharmacokinetics (PK), biodistribution (BD), and therapeutic activity of pegylated liposomal doxorubicin formulations with different drug release rates were studied in an orthotopic 4T1 murine mammary carcinoma model.
Theresa M Allen
exaly +2 more sources
Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin
Journal of Cutaneous Pathology, 2003Background: A new formulation of doxorubicin (pegylated liposomal doxorubicin) has been developed to attenuate the systemic side effects produced by this agent. Although pegylated liposomal doxorubicin has a much lower risk for cardiotoxicity, it has been associated with cutaneous side effects that differ from, and may also be more frequent than ...
Joseph C, English +2 more
openaire +2 more sources
Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
Clinical Breast Cancer, 2003Anthracyclines, particularly conventional doxorubicin, play an important role in the treatment of breast cancer, both in the adjuvant and metastatic settings. However, the benefits of conventional doxorubicin in terms of antitumor activity are limited by its therapeutic index.
openaire +2 more sources
Reversible Ageusia after Chemotherapy with Pegylated Liposomal Doxorubicin
Annals of Pharmacotherapy, 2004OBJECTIVE: To report a case of reversible ageusia in a patient with multiple myeloma receiving pegylated liposomal doxorubicin. CASE SUMMARY: A 67–year-old man with a history of arterial hypertension and ...
Philipp, Kiewe +3 more
openaire +2 more sources
[Doxil--pegylated liposomal doxorubicin].
Gan to kagaku ryoho. Cancer & chemotherapy, 2008Pegylated liposomal doxorubicin (Doxil: PLD) is a liposome-encapsulated form of doxorubicin modified with polyethylene glycol that has been approved for the treatment of AIDS-related Kaposi's sarcoma. The characteristics of PLD are reduction of the severe side effects of cardiac toxicity and myelosuppression seen with doxorubicin, and a higher anti ...
Noritaka, Sekiya, Akifumi, Imamura
openaire +1 more source
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
Cancer Chemotherapy and Pharmacology, 2011There is significant inter-patient variability in the pharmacokinetics of pegylated liposomal doxorubicin (PLD). Identification of factors affecting the pharmacokinetics of PLD would enable personalization of therapy. We previously reported that age, gender, body composition, and monocytes affect the clearance of other liposomal agents.
Ninh M, La-Beck +6 more
openaire +2 more sources
Pegylated liposomal doxorubicin in stage IVB mycosis fungoides
British Journal of Dermatology, 2005Previous studies have shown that pegylated liposomal doxorubicin (LD) is effective in the treatment of relapsing or recalcitrant cutaneous T-cell lymphoma.To evaluate the activity and toxicity of LD in patients with stage IVB mycosis fungoides (MF).In this retrospective study, we evaluated outcomes and recorded adverse effects in 10 patients with MF ...
DI LORENZO, GIUSEPPE +3 more
openaire +4 more sources
Dissociable PEGylation alleviates Kupffer cells capture of PEGylated liposomal doxorubicin
International Journal of PharmaceuticsSurface modification by polyethylene glycol (PEG) is valuable to assist clinical translation of lipid-based nanomedicines but suffering "PEG dilemma" due to unavoidable interaction with anti-PEG antibodies. Considering high detection rates of pre-existing anti-PEG antibodies in clinic, it is urgent to enrich PEGylation strategies to resist anti-PEG ...
Kaisong Tian +7 more
openaire +2 more sources